Favorable outcome of COVID-19 in a young woman with severe Crohn’s disease on regular use of adalimumab and prednisone: a case report
| dc.contributor.author | Vechi, Hareton Teixeira | |
| dc.contributor.author | Maia, Lucas Rodrigues | |
| dc.contributor.author | Alves, Manoela do Monte | |
| dc.contributor.author | Rodrigues-Neto, João Firmino | |
| dc.date.accessioned | 2022-02-18T11:10:29Z | |
| dc.date.available | 2022-02-18T11:10:29Z | |
| dc.date.issued | 2020 | |
| dc.description.resumo | COVID-19 is a viral disease caused by SARS-CoV-2 that compromises the host immune response in severe cases, promoting a hyperinflammation that results in acute lung injury and multiple organs failure. In this context, patients presenting with immune-related diseases, such as Crohn’s disease, affected by COVID-19, may have an uncertain prognosis. We report on a case of a young female patient with a severe Crohn’s disease that presented with COVID-19 pneumonia and a favorable outcome even maintaining the use of adalimumab, TNF - alpha inhibitor and prednisone. This case raises the hypothesis that aside from prednisone, TNF-α inhibitors such as adalimumab could be used to stop the progression to COVID-19 complications by blocking the TNF-alpha-driven inflammatory process that occurs in severe COVID-19 | pt_BR |
| dc.identifier.citation | VECHI, Hareton Teixeira et al. Favorable outcome of COVID-19 in a young woman with severe Crohn’s disease on regular use of adalimumab and prednisone: a case report. Revista do Instituto de Medicina Tropical de São Paulo, [s. l.], v. 62, p. 1-6, 2020. Disponível em: https://www.scielo.br/j/rimtsp/a/G39mZmZfxz3Xnqkn3ff8fby/?lang=en. Acesso em: 16 fev. 2022. http://dx.doi.org/10.1590/s1678-9946202062102 | pt_BR |
| dc.identifier.doi | 10.1590/s1678-9946202062102 | |
| dc.identifier.issn | 1678-9946 (online) | |
| dc.identifier.issn | 0036-4665 (print) | |
| dc.identifier.uri | https://repositorio.ufrn.br/handle/123456789/46067 | |
| dc.language | en | pt_BR |
| dc.publisher | Universidade de São Paulo (USP) | pt_BR |
| dc.rights | Attribution-NonCommercial 3.0 Brazil | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/br/ | * |
| dc.subject | COVID-19 | pt_BR |
| dc.subject | Crohn’s disease | pt_BR |
| dc.subject | TNF inhibitor | pt_BR |
| dc.subject | SARS-CoV-2 | pt_BR |
| dc.title | Favorable outcome of COVID-19 in a young woman with severe Crohn’s disease on regular use of adalimumab and prednisone: a case report | pt_BR |
| dc.type | article | pt_BR |
Arquivos
Pacote Original
1 - 1 de 1
Nenhuma Miniatura disponível
- Nome:
- FavorableOutcomeCovid-19_Vechi_2020.pdf
- Tamanho:
- 601 KB
- Formato:
- Adobe Portable Document Format
Nenhuma Miniatura disponível
Licença do Pacote
1 - 1 de 1
Nenhuma Miniatura disponível
- Nome:
- license.txt
- Tamanho:
- 1.45 KB
- Formato:
- Item-specific license agreed upon to submission
Nenhuma Miniatura disponível